Active, not recruitingNCT04145141
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
Studying Rare tumor of liver and intrahepatic biliary tract
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Tim F Greten, M.D., M.DNational Cancer Institute (NCI)
- Enrollment
- 132 target
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2021 – 2027
Study locations (4)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- University of Texas Southwestern Medical Center, Dallas, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04145141 on ClinicalTrials.govOther trials for Rare tumor of liver and intrahepatic biliary tract
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07356531Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver CancerJIANGSU SHENMING Medical Technology CO., Ltd
- ACTIVE NOT RECRUITINGNANCT02984566Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)University of Sydney
See all trials for Rare tumor of liver and intrahepatic biliary tract →